TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04280692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine
Description: Sub-curative 480mg single dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine
Description: Sub-curative 480mg single dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine
Description: Sub-curative 480mg single dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether lumefantrine
Description: Three day curative regimen 20mg/120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether lumefantrine
Description: Three day curative regimen 20mg/120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether lumefantrine
Description: Three day curative regimen 20mg/120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Single low dose regimen 0.25 mg base/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Single low dose regimen 0.25 mg base/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Single low dose regimen 0.25 mg base/kg
Study: NCT04097054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmented preoperative planning
Description: The study investigates the impact of augmented preoperative planning on OR time variance in complex and rare visceral surgical procedures.
Study: NCT05018182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m² Q2w(2 h) before surgery rection and 130 mg/m² Q3w (2 h) after surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m² ivgtt(1.5 h) Q2w before surgery rection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid 400 mg/m² ivgtt(2 h) Q2w before surgery rection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
Study: NCT05035290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation
Description: Negative pressure ventilation - cuirass will be applied on the patient´s ches and abdomen immediately after extubation
Study: NCT04936763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Janesse 20 (Cross-linked Hyaluronic Acid)
Description: Janesse 20 will be administered at baseline (visit 2, day 0) and, if the Investigator will evaluate necessary, also at day 30 (visit 3). The Investigational device will be injected with retrograde technique (moving backward) with homogeneous amount on the length of each side of Labia Majora. The Janesse 20 dosage administered will be 1 ml in left labia and 1 ml in right labia for each session.
Study: NCT05391347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange oil aromatherapy
Description: 5 minutes before the invasive procedure, 3 ml of orange oil were dripping onto the sponge, and the patient was told to breathe slowly at a distance of 3 cm and to smell during the process.
Study: NCT04818151

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin treatment for VTE

Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban treatment for VTE
Study: NCT05447429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: TAP block will be performed by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 ml saline solution will be injected by a needle which is punctured at the midaxillary line between subcostal margin and iliac crest, once tip of the needle had detected just above the peritoneum the syringe pulled back.
Study: NCT04670029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: APA sessions during chemotherapy with aerobic and anaerobic sessions on site and at home (+ home exercises book if the patient so wishes)
Study: NCT05065580

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment
Description: Individuals will receive the following techniques during weekly OMT (osteopathic manipulative techniques) for a duration of 8 weeks: 1. Suboccipital release 2. Vault hold. 3. Soft tissue techniques at the cervical and shoulder region 4.There will be NO high velocity low amplitude (HVLA) techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment
Description: Individuals will receive the following techniques during weekly OMT (osteopathic manipulative techniques) for a duration of 8 weeks: 1. Suboccipital release 2. Vault hold. 3. Soft tissue techniques at the cervical and shoulder region 4.There will be NO high velocity low amplitude (HVLA) techniques
Study: NCT06647173

Intervention type: BEHAVIORAL
Intervention: Blued+ Service Platform
Description: During the intervention period, participants received the enhanced version of the Blued app. The free HIV prevention services were integrated into the Blued app: health messaging, in-home HIV testing, linkage to care for those testing HIV positive, condoms, lubricants, in-app screening, and provision to PrEP.
Study: NCT06645522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone dexborneol
Description: Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.
Study: NCT06577012

Intervention type: PROCEDURE
Intervention: Small incision lenticule extraction
Description: Small incision lenticule extraction surgeries performed by two Refractive surgery experts (Refractive surgery expert 1: YYF, Associate Professor with 10 years of experience as a refractive surgeon; Refractive surgery expert 2: GF, Associate Professor with 5 years of experience as a refractive surgeon) and a Attending ophthalmologist (XJ, Attending ophthalmologist with 1 year of experience as a refractive surgeon).
Study: NCT05306691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bio-smart Light Cured Protective Shield with bioactive S-PRG (Surface Pre- Reacted Glass ionomer) filler technology (PRG Barrier Coat) by (By SHOFU Inc., Japan).
Description: Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bio-smart Light Cured Protective Shield with bioactive S-PRG (Surface Pre- Reacted Glass ionomer) filler technology (PRG Barrier Coat) by (By SHOFU Inc., Japan).
Description: Surface reaction-type pre-released glass ionomer (S-PRG) fillers containing dental materials are now commercially available. It was shown that PRG filler is an active ingredient with the ability to release and recharge fluoride ions. In addition, S-PRG fillers release five other active ions, Sr2þ, SiO3 2, Naþ, BO3 3, and Al3þ. S-PRG filler has a modulation effect on acidic conditions, causing the surrounding environment to become weakly alkaline upon contact with water or acidic solutions. This effect was thought to be brought by Sr, B, Na, and F ions released from S-PRG filler. A fluoride-releasing coating material containing S-PRG filler (PRG BarrierCoat®, SHOFU, Japan) was manufactured as a coating material to suppress dentin hypersensitivity and prevent caries on smooth surface areas.
Study: NCT05479825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inflation- deflation line combined with ICG fluorography
Description: Identification of the intersegmental plane using inflation- deflation line combined with ICG fluorography under the status of tubeless
Study: NCT05588661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation Exercises
Description: Perturbation exercises will be performed 3 times in a week for 6 weeks for 10-15 minutes per session with baseline treatment for total 30 minutes.~Total 18 sessions will be given to the patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: It will be performed 3 times in a week for 10-15 minutes per session with baseline treatment for total 30 mints.~Total 18 sessions will be given for 6 weeks
Study: NCT05477264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Induction therapy: Tislelizumab combined with radiation~* Tislelizumab: 200mg, IV at 3-week intervals combined with radiotherapy.~* Radiotherapy: 400Gy/20 fractions~Maintenance therapy(after termination of combination therapy)~* Tislelizumab: 200mg IV at 3-week intervals for up to 2 years until disease progression or intolerance.
Study: NCT04993716

Intervention type: OTHER
Intervention: observational
Description: Collect from a bank of biological samples, identification of prognostic factors associated with survival without serious neurological heavy sequelae
Study: NCT05135065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-Assisted Supervision Protocol
Description: Measurement-based supervision protocol that incorporates fidelity measurement from a machine learning tool and feedback reports from this tool into a standardized supervision protocol for behavior therapy to task-shift burdensome supervision tasks to a machine, reducing costs and improving precision of fidelity measurement for agencies.
Study: NCT06499870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Piflufolastat
Description: Undergo fluorine F 18 piflufolastat PET/MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image Guided Radiation Therapy
Description: Undergo IGRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study: NCT04821050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation
Description: A senior acupuncture doctor will pierce filiform needles through the sacral foramen into the S3 and S4 sacral nerves. These sites correspond to the Zhongliao and Xialiao acupoints in Traditional Chinese Medicine.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks.
Study: NCT05869812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaHMB (Dietary supplement, not Drug)
Description: The investigators will focus our effort, for the purposes of this study, on determining if adding an HMB supplement will stimulate positive outcomes and recovery of the quadriceps and hamstrings muscle architecture and function in females with ACL injury requiring surgical repair, more so than a placebo control.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CaLa
Description: Comparative placebo
Study: NCT06635421

Intervention type: OTHER
Intervention: Model of care delivery for long-acting injectable ART
Description: This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).

Intervention type: OTHER
Intervention: Model of care delivery for long-acting injectable ART
Description: This study is assessing a novel model of care delivery, i.e. pharmacist administered long-acting cabotegravir + rilpivirine (CAB+RPV LA). In phase 2 and 3, no medication will be provided by the study. The decision to initiate CAB+RPV LA will be at the discretion of the patient and their provider in accordance with both standard of care and local prescribing practices. This will occur independent of study participation. The study intervention is the model of care for CAB+RPV LA administration. The models of care being studied include (1) pharmacist administered CAB+RPV LA in MetroHealth satellite pharmacy setting (novel model of care); (2) nurse administered CAB+RPV LA in the Infectious Diseases clinic at MetroHealth main campus (current standard of care).
Study: NCT05004623

Intervention type: DEVICE
Group type: OTHER
Intervention: Sentinel Lymph Node Biopsy
Description: Detection of sentinel lymph nodes by indocyanine green (ICG) fluorescent dye technique, using a prototype of the Easy Light device.
Study: NCT04821050

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Shallow acupuncture stimulation will be performed at sites 8-10cm away from the acupoints in Group 1.~Electrodes will be clamped on the filiform needles and an electrical current of 0.5 mA will be delivered. The stimulation will last for 60 minutes every time, once a day for 2 weeks.
Study: NCT05263388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REKOVELLE (Follitropin Delta)
Description: REKOVELLE administered as single daily subcutaneous injections in the abdomen. The starting dose of REKOVELLE is 15 μg fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the gonadotropin-releasing hormone (GnRH) antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily REKOVELLE dose can be increased or decreased by 5 μg based on the subject's response. The minimum REKOVELLE dose is 5 μg and the maximum REKOVELLE is 20 μg. Subjects can be treated for a maximum of 20 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GONAL-F (Follitropin Alfa)
Description: GONAL-F administered as single daily subcutaneous injections in the abdomen. The starting dose of GONAL-F is 225 IU fixed for the first four stimulation days. Dose adjustments may be implemented on the day of starting the GnRH antagonist (stimulation day 5 or day 6) or later, can occur no more frequently than every second day. At each dose adjustment, the daily GONAL-F dose may be adjusted by 75 IU based on the subject's response. The minimum GONAL-F dose is 75 IU and the maximum GONAL-F dose is 300 IU. Subjects can be treated for a maximum of 20 days.
Study: NCT06528860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight® 1 day soft contact lenses
Description: Dual-focus contact lenses, daily disposable, material: omafilcon A, water content: 60%.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Proclear® 1 day soft contact lenses
Description: Single-vision contact lenses, daily disposable, material: omafilcon A, water content: 60%.
Study: NCT04535271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Study: NCT05152979

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verb Network Strengthening Treatment (VNeST)
Description: Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verb Network Strengthening Treatment (VNeST)
Description: Participants are presented with a verb (representing an activity, for example, driving) orally and in writing. The participants are first asked to name someone who may perform the given activity (an agent, for example, a chauffeur), then to name an object which the given activity may be performed with (a patient, for example, a limousine). Several types of semantic clues and assistance are provided if the participant is having difficulties finding adequate nouns. This procedure is repeated for three different agents and objects related to the given verb. The participants are then asked to choose one of the three phrases participants have created and expand on it by telling where, when and why the agent is performing the activity. After this the participant are given sentences (with several foils) including the activity as well as agents and patients, and are asked to indicate whether the sentences are correct or not.
Study: NCT06358482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oscillating toothbrush
Description: oscillating toothbrush
Study: NCT05792410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Dalpiciclib Isethionate Tablets
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets：Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Fulvestrant
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant：Injection, 5 ml: 0.25g/bottle, intramuscular
Study: NCT06358482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard manual toothbrush
Description: standard manual toothbrush
Study: NCT05792410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 & Bevacizumab injection
Description: SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip
Study: NCT05534451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video laryngoscope guided nasotracheal intubation
Description: According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video rigid laryngoscope guided nasotracheal intubation
Description: According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be divided into video rigid laryngoscope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video fiberoptic scope guided nasotracheal intubation
Description: According to the kinds of video methods uesd to assist in nasotracheal intubation, participants will be randomly divided into video fiberoptic scope group. The data of the duration of catheter reaching oropharynx (T1), the duration of catheter reaching glottis (T2), successful intubation time (T3), the first-attempt intubation success rate, the total number of intubations for each participant, whether there is oral and nasal mucosa bleeding, whether the tracheal ring is pressed, whether the catheter is rotated, the heraodynamic changes, and the occurrence of throat complications within 2 hours after surgery, will be recorded respectively.
Study: NCT05826769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy- Protein Enriched Nutritional Formula
Description: EN volume will start at 1 mL/kg/h and then increase by 1 mL/kg every 6 hours if tolerated, until reaching 130 mL/kg/d.
Study: NCT05079152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX+PPV23;COVAX+IIV4
Description: 1st dose : combined vaccination of COVAX+PPV23; 2nd dose: combined vaccination of COVAX+IIV4

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX only (1st and 2nd dose)
Description: 1st dose: COVAX only; 2nd dose: COVAX only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23 for the 1st dose and IIV4 for the 2nd dose
Description: 1st dose: PPV23 only; 2nd dose: IIV4 only
Study: NCT05100394

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Therapeutic laser therapy was applied.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound + Moist Heat pack + Exercises
Description: Ultrasound therapy, a moist heat pack, and a home exercise program were given.